This correlates to 4x increase in exon skipping compared to the 20 mgkg cohort of SRP5051 at 12 weeks mean exon skipping of 257 n2 and an 18x increase in exon skipping compared to a weekly 30 mgkg dose of eteplirsen at 24 weeks mean exon skipping of 059 n16